

11. (Amended) Colostrinin according to claim 9[, 10 or 11], for use in the treatment of chronic bacterial and/or viral infections.

12. (Amended) Colostrinin [according to any preceding claim,] wherein said Colostrinin is derived from a non-ovine source.

20. (Amended) The use according to claim 18 [or 19], or the treatment of diseases with a bacterial and viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

21. (Amended) The use according to claim 18[, 19 or 20], for the treatment of bacterial and/or viral infections.

22. (Amended) The use according to claim [any one of claims] 18 [to 21], wherein said Colostrinin is non-ovine Colostrinin.

26. (Amended) A method according to claim 23[, 24 or 25], wherein the Colostrinin is non-ovine Colostrinin.

27. (Amended) A method according to claim [any one of claims 23 to] 26, [comprising] wherein said predetermined amount of Colostrinin is in the range of about 25 to 2000 micrograms.

30. (Amended) A method according to claim 28 [or 29], wherein the cycle is repeated at least once.

33. (Amended) A composition according to claim 31 [or 32], in a form suitable for injection.

34. (Amended) A composition according to claim 31 [or 32], in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.